{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:33:13Z","timestamp":1777627993406,"version":"3.51.4"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Grant Agency of the Charles University in Prague","award":["SVV\/2017\/260 414"],"award-info":[{"award-number":["SVV\/2017\/260 414"]}]},{"DOI":"10.13039\/501100001824","name":"Czech Science Foundation","doi-asserted-by":"crossref","award":["17-16169S"],"award-info":[{"award-number":["17-16169S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0202706","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T13:44:36Z","timestamp":1534427076000},"page":"e0202706","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)"],"prefix":"10.1371","volume":"13","author":[{"given":"Martina","family":"Ceckova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josef","family":"Reznicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin F.","family":"Fromm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-097X","authenticated-orcid":true,"given":"Frantisek","family":"Staud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"key":"ref1","article-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","year":"2017"},{"key":"ref2","unstructured":"WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach\u2013 2nd Edition. 2016."},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/17512433.2016.1221760","article-title":"Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen","volume":"9","author":"JP Mouton","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref4","first-page":"1","article-title":"Assessment of the effect of antiretroviral therapy on renal and liver functions among HIV-infected patients: a retrospective study","volume":"9","author":"H Wondifraw Baynes","year":"2017","journal-title":"HIV AIDS (Auckl)"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cpdd.313","article-title":"Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications","volume":"6","author":"CJ Bednasz","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2009.10.001","article-title":"The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters","volume":"31","author":"O Kis","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pharmtox-010611-134529","article-title":"Drug transporters in drug efficacy and toxicity","volume":"52","author":"MK DeGorter","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/clpt.2010.354","article-title":"Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions","volume":"89","author":"O Zolk","year":"2011","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","article-title":"Cloning and characterization of two human polyspecific organic cation transporters","volume":"16","author":"V Gorboulev","year":"1997","journal-title":"DNA and Cell Biology"},{"issue":"50","key":"ref10","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","article-title":"A human transporter protein that mediates the final excretion step for toxic organic cations","volume":"102","author":"M Otsuka","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref11","article-title":"Committee for Human Medicinal Products: Concept paper on a revision of the Guideline on the 4 investigation of drug interactions","year":"2017"},{"key":"ref12","article-title":"Clinical Pharmacology","year":"2012"},{"issue":"5","key":"ref13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/clpt.2012.126","article-title":"Highlights from the International Transporter Consortium second workshop","volume":"92","author":"MJ Zamek-Gliszczynski","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"ref14","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s11095-006-0279-5","article-title":"Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier","volume":"23","author":"G Dirson","year":"2006","journal-title":"Pharm Res"},{"issue":"10","key":"ref15","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2007.01.027","article-title":"Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein","volume":"73","author":"CH Storch","year":"2007","journal-title":"Biochemical Pharmacology"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1023\/A:1016430825740","article-title":"Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture","volume":"19","author":"E Stormer","year":"2002","journal-title":"Pharm Res"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpba.2017.01.012","article-title":"Universal efavirenz determination in transport study, rat placenta perfusion and placenta lysate by HPLC-UV","volume":"137","author":"L Zelena","year":"2017","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/dmd.106.012765","article-title":"Inhibition of MRP1\/ABCC1, MRP2\/ABCC2, and MRP3\/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors","volume":"35","author":"J Weiss","year":"2007","journal-title":"Drug Metabolism and Disposition"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","article-title":"Modulation of human BCRP (ABCG2) activity by anti-HIV drugs","volume":"59","author":"J Weiss","year":"2007","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1124\/dmd.108.020826","article-title":"Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection","volume":"36","author":"N Jung","year":"2008","journal-title":"Drug Metabolism and Disposition"},{"key":"ref21","first-page":"78","article-title":"Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter","volume":"6","author":"DM Moss","year":"2015","journal-title":"Front Pharmacol"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0009-9236(96)90183-6","article-title":"Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole","volume":"59","author":"KH Moore","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/jpet.108.146225","article-title":"Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3","volume":"329","author":"G Minuesa","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.bcp.2013.07.008","article-title":"Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine","volume":"86","author":"F M\u00fcller","year":"2013","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1128\/AAC.00648-16","article-title":"Role of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine","volume":"60","author":"M Ceckova","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1476-5381.2010.01052.x","article-title":"Double-transfected MDCK cells expressing human OCT1\/MATE1 or OCT2\/MATE1: determinants of uptake and transcellular translocation of organic cations","volume":"163","author":"J K\u00f6nig","year":"2011","journal-title":"Br J Pharmacol"},{"key":"ref27","year":"2011"},{"key":"ref28","year":"1986"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00228-014-1770-2","article-title":"N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction","volume":"71","author":"F Muller","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"ref30","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/00002030-200106150-00023","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients","volume":"15","author":"C Marzolini","year":"2001","journal-title":"Aids"},{"issue":"5","key":"ref31","doi-asserted-by":"crossref","first-page":"595","DOI":"10.3109\/00498258709043966","article-title":"Dose-dependent pharmacokinetics of cimetidine in the rat","volume":"17","author":"A Adedoyin","year":"1987","journal-title":"Xenobiotica"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1124\/jpet.111.184986","article-title":"Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney","volume":"340","author":"S Ito","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/jpet.108.147918","article-title":"Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells","volume":"329","author":"M Tsuda","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"13","key":"ref34","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1021\/jm2001629","article-title":"Profiling of a Prescription Drug Library for Potential Renal Drug-Drug Interactions Mediated by the Organic Cation Transporter 2","volume":"54","author":"Y Kido","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1211\/0022357021771814","article-title":"Uptake of lamivudine by rat renal brush border membrane vesicles","volume":"54","author":"T Takubo","year":"2002","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1211\/0022357001774011","article-title":"Effect of trimethoprim on the renal clearance of lamivudine in rats","volume":"52","author":"T Takubo","year":"2000","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00003088-199936010-00004","article-title":"Clinical pharmacokinetics of lamivudine","volume":"36","author":"MA Johnson","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/clpt.2013.77","article-title":"Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium","volume":"94","author":"D Tweedie","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the International Transporter Consortium","volume":"94","author":"KM Hillgren","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007691-200406000-00008","article-title":"Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects","volume":"26","author":"L Stahle","year":"2004","journal-title":"Ther Drug Monit"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/jac\/dki308","article-title":"Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals","volume":"56","author":"LM Almond","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2007.02944.x","article-title":"The effect of ABCG2 V12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine","volume":"64","author":"HS Kim","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1002\/jps.21744","article-title":"Comparison of bidirectional lamivudine and zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers","volume":"98","author":"J de Souza","year":"2009","journal-title":"J Pharm Sci"},{"key":"ref44","article-title":"Sustiva Prescribing Information","author":"B-MS Company","year":"2015"},{"issue":"10","key":"ref45","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.ki.5002134","article-title":"Nephrotoxicity of antiretroviral therapy in an HIV-infected patient","volume":"71","author":"SM Said","year":"2007","journal-title":"Kidney International"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00002030-200101050-00027","article-title":"Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors","volume":"15","author":"AAM Morris","year":"2001","journal-title":"Aids"},{"issue":"1","key":"ref47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/apc.2011.0185","article-title":"Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir","volume":"26","author":"P Maggi","year":"2012","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00498254.2016.1158886","article-title":"Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters","volume":"47","author":"J Reznicek","year":"2017","journal-title":"Xenobiotica"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0202706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T11:06:33Z","timestamp":1540033593000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0202706"}},"subtitle":[],"editor":[{"given":"Markos","family":"Leggas","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":48,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0202706","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]}}}